Therapeutic approaches for intravascular microthrombi-induced acute respiratory distress syndrome (ARDS) in COVID-19 infection.
Curr Pharm Biotechnol
; 2022 Jul 13.
Article
in English
| MEDLINE | ID: covidwho-2323328
ABSTRACT
The COVID-19 pandemic has overwhelmed our health care capacity in an unprecedented way due to the sheer number of critically infected patients admitted to hospitals during the last two years. Endothelial injury is seen as one of the central hallmarks of COVID-19 infection that is the starting point in the generation of microthrombi and sepsis eventually leading to acute respiratory distress syndrome (ARDs) and multi-organ failure. The dramatic fall in lung function during ARDs is attributed to the microthrombi-induced coagulopathy primed by a hyperactive immune system. Due to the lack of effective antiviral agents, the line of treatment is limited to the management of two key risk factors i.e., immune activation and coagulopathy. In the present review, we describe the mechanistic role, therapeutic targets and opportunities to control immune activation and coagulopathy during the pathogenesis of COVID-19-induced ARDs.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Prognostic study
Language:
English
Journal subject:
Biotechnology
/
Pharmacology
Year:
2022
Document Type:
Article
Affiliation country:
1389201023666220713113713
Similar
MEDLINE
...
LILACS
LIS